B Cell News and Research

RSS

Biodesix announces expanded Bio-Rad Laboratories partnership agreement to develop Droplet Digital™ PCR high complexity assays

Biodesix, Inc., a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of in vitro diagnostic (IVD) assays to enable highly sensitive detection of multiple genomic markers focused on oncology applications, utilizing Bio-Rad's Droplet Digital™ PCR (ddPCR™) technology on Bio-Rad's QX600 platform.

23 Oct 2025

Disruption of glial circadian rhythms linked to Alzheimer's disease progression

Alzheimer's disease is notorious for scrambling patients' daily rhythms. Restless nights with little sleep and increased napping during the day are early indicators of disease onset, while sundowning, or confusion later in the day, is typical for later stages of the disease.

23 Oct 2025

Drug shows striking success in treating children with multi-metastatic Ewing sarcoma

Ewing sarcoma is one of the most common bone cancers seen in children, and if it spreads, it can be deadly. One study found that under a quarter of children with multi-metastatic Ewing sarcoma survived five years after their diagnosis.

23 Oct 2025

Novel molecule found to be a key player in kidney injury and repair

Chronic kidney disease (CKD) is a progressive condition in which the kidneys gradually lose their ability to filter waste from the blood.

23 Oct 2025

Study: Common test to assess viability of IVF embryos may be flawed

A test deployed in many fertility clinics to assess the viability of embryos for use in IVF is likely to overestimate the number of embryos with abnormalities, suggests a study published today.

23 Oct 2025

Officials show little proof that new tech will help Medicaid enrollees meet work rules

This summer, the state of Louisiana texted just over 13,000 people enrolled in its Medicaid program with a link to a website where they could confirm their incomes.

23 Oct 2025

A new way to monitor chemotherapy drug behavior inside cells

Scientists have made incredible progress in developing cancer therapies that help patients across cancer types.

22 Oct 2025

New type of immunotherapy could change the treatment plan for triple-negative breast cancer

Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main targets that make other types of breast cancers more treatable with powerful therapies.

22 Oct 2025

New study solves lung transplant rejection mystery

More than 50% of lung-transplant recipients experience a rejection of their new lung within five years of receiving it, yet the reason why this is such a prevalent complication has remained a medical mystery.

22 Oct 2025

Study sheds light on how aging unfolds in pets and humans

Scientists have long sought measurable signs in the body, called biomarkers, that reliably reveal our biological age or predict future health issues.

22 Oct 2025

New computer model lets researchers simulate how brain circuits make decisions

Every day, your brain makes thousands of decisions under uncertainty. Most of the time, you guess right. When you don't, you learn. But when the brain's ability to judge context or assign meaning falters, thoughts and behavior can go astray.

22 Oct 2025

Nuclear binding protein identified as key contributor to trisomy 21-related CHDs

Three copies of chromosome 21 causes Down syndrome (DS), and roughly half of children born each year in the United States with DS-approximately 2,600-also have congenital heart defects (CHDs).

22 Oct 2025

Pathogenic bacteria can block gut’s natural defense to spread infection

When harmful bacteria that cause food poisoning, such as E. coli, invade through the digestive tract, gut cells usually fight back by pushing infected cells out of the body to stop the infection from spreading.

22 Oct 2025

HMGN1 gene linked to heart problems in people with Down syndrome

Nearly half of all babies born with Down syndrome face congenital heart defects, often involving serious malformations that require surgery in the first months of life.

22 Oct 2025

Study forces a textbook rewrite on cell division

Scientists at the Ruđer Bošković Institute (RBI) in Zagreb, Croatia, have discovered that the protein CENP-E, long believed to act as a motor dragging chromosomes into place during cell division, in fact plays a completely different role in chromosome movement.

22 Oct 2025

Researchers gain new insights into aging based on studies in dogs

Lab-based studies have provided lots of information on the biology of aging, but it's unclear how lab discoveries apply to aging in the real world. Research in Aging Cell provides insights into aging based on studies in dogs.

22 Oct 2025

Groundbreaking 3D dynamic cell co-culture models simulate MASLD progression

In a recent work published in BME Frontiers, a collaborative study by researchers from Griffith University, Queensland University of Technology, University of Queensland, and Nanjing Stomatological Hospital has introduced groundbreaking three-dimensional (3D) dynamic cell co-culture models to simulate metabolic dysfunction-associated steatotic liver disease (MASLD) progression stages.

22 Oct 2025

New drug combination shows promise in treating colorectal cancer

Colorectal cancer is one of the most common tumors among people over the age of 50. Although it is known to develop from small lesions or polyps, its exact causes are unknown — only a few risk factors are known — and it is usually treated with surgery, chemotherapy and radiotherapy, or biological therapies.

22 Oct 2025

The future of automation: Machine learning–driven hepatocyte and organoid counting

DeNovix discusses how customer demand inspired the development of specialized CellDrop applications for hepatocytes and organoids.

From DeNovix Inc. 22 Oct 2025

$VT3989 shows promising antitumor activity in refractory mesothelioma patients$

VT3989 shows promising antitumor activity in refractory mesothelioma patients

The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to results from a trial led by researchers from The University of Texas MD Anderson Cancer Center.

22 Oct 2025